InVivo Therapeutics Holdings Corp. (NVIV) Reaches $0.52 52-Week Low; Last Week Medifast, Inc. (MED) Coverage

February 6, 2018 - By Winifred Garcia

Among 3 analysts covering Medifast (NYSE:MED), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Medifast had 7 analyst reports since August 10, 2015 according to SRatingsIntel. On Monday, January 11 the stock rating was upgraded by Sidoti to “Buy”. The firm earned “Neutral” rating on Monday, November 30 by Sidoti. The stock of Medifast, Inc. (NYSE:MED) has “Hold” rating given on Friday, January 29 by Wunderlich. DA Davidson initiated it with “Buy” rating and $65.0 target in Wednesday, August 16 report. The stock of Medifast, Inc. (NYSE:MED) earned “Hold” rating by Zacks on Monday, August 10. Sidoti upgraded the shares of MED in report on Monday, October 5 to “Buy” rating. The stock of Medifast, Inc. (NYSE:MED) earned “Buy” rating by DA Davidson on Friday, September 15. See Medifast, Inc. (NYSE:MED) latest ratings:

15/09/2017 Broker: DA Davidson Rating: Buy Old Target: $65 New Target: $74 Maintain
16/08/2017 Broker: DA Davidson Rating: Buy New Target: $65.0 Initiate

The stock of InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) hit a new 52-week low and has $0.50 target or 4.00% below today’s $0.52 share price. The 9 months bearish chart indicates high risk for the $17.84M company. The 1-year low was reported on Feb, 6 by If the $0.50 price target is reached, the company will be worth $713,440 less. The stock increased 1.07% or $0.01 during the last trading session, reaching $0.52. About 18,620 shares traded. InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) has declined 65.27% since February 6, 2017 and is downtrending. It has underperformed by 81.97% the S&P500.

The stock increased 1.18% or $0.78 during the last trading session, reaching $66.99. About 6,309 shares traded. Medifast, Inc. (NYSE:MED) has risen 25.81% since February 6, 2017 and is uptrending. It has outperformed by 9.11% the S&P500.

Investors sentiment decreased to 1 in Q3 2017. Its down 0.11, from 1.11 in 2017Q2. It fall, as 15 investors sold Medifast, Inc. shares while 60 reduced holdings. 31 funds opened positions while 44 raised stakes. 10.20 million shares or 2.70% less from 10.48 million shares in 2017Q2 were reported. New York State Teachers Retirement Sys has 11,336 shares. Texas Permanent School Fund reported 7,664 shares stake. Td Asset has 0% invested in Medifast, Inc. (NYSE:MED). Price T Rowe Assocs Md holds 0% or 3,630 shares in its portfolio. Blackrock reported 1.49 million shares or 0% of all its holdings. Legal & General Group Inc Public Ltd has 19,180 shares. Mufg Americas invested 0% of its portfolio in Medifast, Inc. (NYSE:MED). Numeric Invsts Ltd Liability Co invested in 150,716 shares or 0.07% of the stock. Virginia Retirement Systems Et Al owns 23,100 shares or 0.02% of their US portfolio. 15,090 are owned by Brown Advisory. 41,643 are held by Qs Invsts Ltd. Aqr Capital Management Llc reported 40,823 shares. 13,000 are held by Strs Ohio. Kbc Grp Incorporated Nv holds 0.01% or 20,198 shares in its portfolio. Citadel Advisors Limited Liability Company reported 13,002 shares or 0% of all its holdings.

Medifast, Inc., through its subsidiaries, produces, distributes, and sells weight loss, weight management, healthy living products, and other consumable health and diet products. The company has market cap of $799.43 million. The firm offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, eggs, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape For Life, Flavors of Home, and Essential 1 brands, as well as Dual Fuel, a sports nutrition pilot program. It has a 32.98 P/E ratio. It also provides meal replacements comprising vitamins and minerals; and hydration products, as well as other nutrients for health purposes.

Analysts await InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) to report earnings on March, 9. They expect $-0.16 EPS, up 23.81% or $0.05 from last year’s $-0.21 per share. After $-0.28 actual EPS reported by InVivo Therapeutics Holdings Corp. for the previous quarter, Wall Street now forecasts -42.86% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: